The COX-2 Trail
A Report by Stephanie Sugars

¹www.gettingwell.com/drug_info/rxdrugprofiles/drugs/CEL1078.shtml

²www.gettingwell.com/drug_info/rxdrugprofiles/drugs/VIO1533.shtml

³Press release Popular Arthritic Medication May Prevent Colon Cancer, Prevention of Colon Cancer Focus of Columbia Presbyterian Medical Center Study. www.nyp.org/news/2002/2.19.2002.html

⁴Wallace, Jeanne. Nutritional and Botanical Modulation of the Inflammatory Cascade - Eicosanoids, Cyclooxygenases, and Lipoxygenases- As an Adjunct in Cancer Therapy. Integrative Cancer Therapies 1(1); 2002:7

⁵Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G. FAP Study Group. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002 Jun;50(6):857-60

⁶Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. What is the long-term effectiveness of the nonsteroidal anti-inflammatory drug (NSAID), sulindac, in reducing adenomas in the retained rectal segments of patients with familial adenomatous polyposis (FAP)? Gastroenterology. 2002;122(3):641-645

⁷Giardiello, F. M. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med. 346, 1054–1059 (2002)

⁸www.forbes.com/2002/04/25/0425celebrex.html

⁹Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999 Jun 17;340(24):1888-99. Review. No abstract available.
PMID: 10369853 [PubMed - indexed for MEDLINE]

¹⁰Mintzes B. For and against: Direct to consumer advertising is medicalising normal human experience. BMJ. 2002 Apr 13;324(7342):908-9. No abstract available.
PMID: 11950745 [PubMed - indexed for MEDLINE]

¹¹Manufacturing Need, Manufacturing "Knowledge". National Women's Health Network. May/June 2002 :1-4. www.womenshealthnetwork.org

¹²Widely used arthritis pills may be new treatment for cancer. Cancer Weekly. April 23, 2002. NewsRx.com

¹³ Wooltorton, Eric. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ: Canadian Medical Association Journal. 6/25/2002. Vol. 166, Issue 13, p1692, 2p, 1 graph

¹⁴Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002 Jun 1;324(7349):1287-8. No abstract available.
PMID: 12039807 [PubMed - indexed for MEDLINE]

¹⁵Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55.
PMID: 10979111 [PubMed - indexed for MEDLINE]

¹⁶www.citizen.org/publications/release.cfm?ID=5069

© 2002 by Stephanie Sugars, all rights reserved, used by permission. No part of this article may be reproduced in any form without written permission from the author.

Contact Stephanie Sugars at PJ4Steph@aol.com

Update: 21.May'04